{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T21:59:39Z","timestamp":1772143179781,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T00:00:00Z","timestamp":1700006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T00:00:00Z","timestamp":1700006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-023-04682-8","type":"journal-article","created":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T06:01:41Z","timestamp":1700028101000},"page":"3829-3838","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Jorge clinical study: 10-year outcomes of risk-adapted radiotherapy defined by multiparametric MRI for prostate cancer"],"prefix":"10.1007","volume":"41","author":[{"given":"Victor","family":"Duque-Santana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Diaz-Gavela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Recio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Leonardo","family":"Guerrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"L\u00f3pez-Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Israel J.","family":"Thuissard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Andreu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Sanz-Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9rane","family":"Achard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"G\u00f3mez-Iturriaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yolanda","family":"Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elia","family":"Del Cerro Pe\u00f1alver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7233-0234","authenticated-orcid":false,"given":"Felipe","family":"Cou\u00f1ago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,15]]},"reference":[{"issue":"3","key":"4682_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and morality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"4682_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/JU.0000000000002757","volume":"208","author":"JA Eastham","year":"2022","unstructured":"Eastham JA, Auffenberg GB, Barocas DA, Chou R, Crispino T, Davis JW (2022) Clinically Localized Prostate Cancer: AUA\/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management. J Urol 208(1):10","journal-title":"J Urol"},{"key":"4682_CR3","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1002\/cncr.25477","volume":"117","author":"SJ Freedland","year":"2011","unstructured":"Freedland SJ (2011) Screening, risk assessment, and the approach to therapy in patients with prostate cancer. Cancer 117:1123\u20131135","journal-title":"Cancer"},{"key":"4682_CR4","unstructured":"Mottet N, Bergh RCN, Van Den,et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer March 2023; https:\/\/uroweb.org\/guidelines"},{"key":"4682_CR5","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.eururo.2013.09.046","volume":"65","author":"A Heidenreich","year":"2014","unstructured":"Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T et al (2014) EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 65:124\u2013137","journal-title":"Eur Urol"},{"key":"4682_CR6","doi-asserted-by":"crossref","unstructured":"Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1. Screening, diagnosis, and local treatment with curative intent. Eur Urol 2017; 71:618\u2013629","DOI":"10.1016\/j.eururo.2016.08.003"},{"issue":"7","key":"4682_CR7","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/j.1464-410X.2005.05449.x","volume":"95","author":"J Philip","year":"2005","unstructured":"Philip J, Dutta Roy S, Ballal M, Foster CS (2005) avl\u00e9 P Is a digital rectal examina- tion necessary in the diagnosis and clinical staging of early prostate cancer? BJU Int 95(7):969\u2013971","journal-title":"BJU Int"},{"issue":"369\u2013375","key":"4682_CR8","first-page":"5","volume":"83","author":"K Chamie","year":"2014","unstructured":"Chamie K, Sonn GA, Finley DS, Tan N, Margolis DJ, Raman SS et al (2014) The role of magnetic resonance imaging in delineating clinically significant prostate cancer. Urology 83(369\u2013375):5","journal-title":"Urology"},{"issue":"19","key":"4682_CR9","first-page":"1767","volume":"378","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH et al (2018) MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis N Engl J Med 378(19):1767","journal-title":"MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis N Engl J Med"},{"key":"4682_CR10","doi-asserted-by":"crossref","unstructured":"Cou\u00f1ago F, Cerro E, Aurora A, Gavela D, Marcos FJ, Recio M, et al. Tumor staging using 3 . 0 T multiparametric MRI in prostate cancer : impact on treatment decisions for radical radiotherapy. Springerplus. 2015 Dec 18;4:789.","DOI":"10.1186\/s40064-015-1596-0"},{"key":"4682_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/09553002.2018.1415041","volume":"94","author":"A Gomez-iturriaga","year":"2018","unstructured":"Gomez-iturriaga A, Casquero F, Urresola A, Ezquerro A, Villeirs GM, Bossi A et al (2018) Pretreatment Multiparametric Magnetic Resonance Imaging Findings Are More Accurate Independent Predictors of Outcome Than Clinical Variables in Localized Prostate Cancer. Radiat Oncol Biol 94:1\u20137","journal-title":"Radiat Oncol Biol"},{"issue":"3","key":"4682_CR12","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2214\/AJR.19.21836","volume":"214","author":"S Han","year":"2020","unstructured":"Han S, Kim T, Westphalen AC, Hricak H, Zelefsky MJ, Vargas HA et al (2020) Prognostic Value of Pretreatment MRI in Patients With Prostate. JR Am J Roentgenol 214(3):597\u2013604","journal-title":"JR Am J Roentgenol"},{"issue":"6","key":"4682_CR13","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.brachy.2017.07.008","volume":"16","author":"JV Hegde","year":"2017","unstructured":"Hegde JV, Demanes DJ, Veruttipong D, Raince J, Park S, Raman SS et al (2017) Pretreatment 3T multiparametric MRI staging predicts for biochemical failure in high-risk prostate cancer treated with combination high-dose-rate brachytherapy and external beam radiotherapy. Brachytherapy 16(6):1106\u20131112","journal-title":"Brachytherapy"},{"issue":"10","key":"4682_CR14","doi-asserted-by":"publisher","first-page":"471.e11","DOI":"10.1016\/j.urolonc.2018.07.004","volume":"36","author":"G Kauffmann","year":"2018","unstructured":"Kauffmann G, Arif F, Patel P, Oto A, Liauw SL (2018) Pretreatment multiparametric MRI is independently associated with biochemical outcome in men treated with radiation therapy for prostate cancer. Urol Oncol 36(10):471.e11-471.e18","journal-title":"Urol Oncol"},{"key":"4682_CR15","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1007\/s00330-011-2377-y","volume":"22","author":"OJ Barentsz","year":"2012","unstructured":"Barentsz OJ, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G et al (2012) Esur prostate MR guidelines 2012. Eur Radiol 22:746\u2013757","journal-title":"Eur Radiol"},{"issue":"6","key":"4682_CR16","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/j.1754-9485.2010.02214.x","volume":"54","author":"AJ Hayden","year":"2010","unstructured":"Hayden AJ, Martin JM, Kneebone AB, Lehman M, Wiltshire KL, Skala M et al (2010) Australian & New Zealand Faculty of Radiation Oncology Genito-Urinary Group: 2010 consensus guidelines for definitive external beam radiotherapy for prostate carcinoma. J Med Imaging Radiat Oncol 54(6):513\u2013525","journal-title":"J Med Imaging Radiat Oncol"},{"key":"4682_CR17","doi-asserted-by":"crossref","unstructured":"Zapatero A, Guerrero A, Maldonado X, et al. High\u2011dose radiotherapy with short\u2011 term or long\u2011term androgen deprivation in localised prostate cancer (DART01\/05 GICOR): a randomised, controlled, phase 3 trial. Lancet Oncol. 16:320\u2013327","DOI":"10.1016\/S1470-2045(15)70045-8"},{"key":"4682_CR18","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","volume":"65","author":"M Roach 3rd","year":"2006","unstructured":"Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965\u2013974","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"4682_CR19","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(22)00190-5","volume":"23","author":"A Zapatero","year":"2022","unstructured":"Zapatero A, Guerrero A, Maldonado X, \u00c1lvarez A, San-Segundo CG, Rodr\u00edguez M\u00c1C et al (2022) High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01\/05): 10-year results of a phase 3 randomised, controlled trial. Lancet Oncol 23(5):671\u2013681","journal-title":"Lancet Oncol"},{"key":"4682_CR20","doi-asserted-by":"crossref","unstructured":"Panje C, Panje T, Putora PM, et l. Guidance of treatment decisions in risk-adapted primary radiotherapy for prostate cancer using multiparametric magnetic resonance imaging: a single center experience. Radiat Oncol. 2015 Feb 22;10:47.","DOI":"10.1186\/s13014-015-0338-3"},{"key":"4682_CR21","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/1754-9485.12107","volume":"58","author":"JH Chang","year":"2014","unstructured":"Chang JH, Lim Joon D, Nguyen BT et al (2014) MRI scans significantly change target coverage decisions in radical radiotherapy for prostate cancer. J Med Imaging Radiat Oncol 58:237\u2013243","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"11","key":"4682_CR22","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1200\/JCO.20.03282","volume":"39","author":"V Murthy","year":"2021","unstructured":"Murthy V, Maitre P, Kannan S et al (2021) Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial. J Clin Oncol 39(11):1234\u20131242","journal-title":"J Clin Oncol"},{"issue":"2","key":"4682_CR23","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"WJ Morris","year":"2017","unstructured":"Morris WJ, Tyldesley S, Rodda S et al (2017) Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer. Int J Radiat Oncol Biol Phys 98(2):275\u2013285","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"4682_CR24","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1200\/JCO.20.02873","volume":"39","author":"LGW Kerkmeijer","year":"2021","unstructured":"Kerkmeijer LGW, Groen VH, Pos FJ et al (2021) Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial. J Clin Oncol 39(7):787\u2013796","journal-title":"J Clin Oncol"},{"issue":"5","key":"4682_CR25","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.eururo.2022.07.011","volume":"82","author":"TM Ma","year":"2022","unstructured":"Ma TM, Chu FI, Sandler H, Feng FY, Efstathiou JA, Jones CU et al (2022) Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN). Eur Urol 82(5):487\u2013498","journal-title":"Eur Urol"},{"issue":"e0210514","key":"4682_CR26","first-page":"29","volume":"14","author":"F Goupy","year":"2019","unstructured":"Goupy F, Supiot S, Pasquier D et al (2019) Intensity-modulated radiotherapy for prostate cancer with seminal vesicle involvement (T3b): a multicentric retrospec- tive analysis. PLoS ONE 14(e0210514):29","journal-title":"PLoS ONE"},{"issue":"665\u2013671","key":"4682_CR27","first-page":"32","volume":"73","author":"T Joseph","year":"2009","unstructured":"Joseph T, McKenna DA, Westphalen AC et al (2009) Pretreatment endorectal magnetic resonance im- aging and magnetic resonance spectroscopic im- aging features of prostate cancer as predictors of response to external beam radiotherapy. Int J Ra- diat Oncol Biol Phys 73(665\u2013671):32","journal-title":"Int J Ra- diat Oncol Biol Phys"},{"issue":"6","key":"4682_CR28","doi-asserted-by":"publisher","first-page":"600.e1","DOI":"10.1016\/j.urolonc.2019.12.015","volume":"38","author":"WT Turchan","year":"2020","unstructured":"Turchan WT, Kauffmann G, Patel P, Oto A, Liauw SL (2020) PI-RADS score is associated with biochemical control and distant metastasis in men with intermediate-risk and high-risk prostate cancer treated with radiation therapy. Urol Oncol 38(6):600.e1-600.e8","journal-title":"Urol Oncol"},{"key":"4682_CR29","doi-asserted-by":"crossref","unstructured":"G. Attard, L.R. Murphy, N.W. Clarke, et al. Comparison of abiraterone acetate and prednisolone (AAP) or combination enzalutamide (ENZ) + AAP for metastatic hormone sensitive prostate cancer (mHSPC) starting androgen deprivation therapy (ADT): Overall survival (OS) results of 2 randomised phase III trials from the STAMPEDE protocol. Annals of Oncology (2022) 33 (suppl_7): S808-S869","DOI":"10.1016\/j.annonc.2022.08.065"},{"key":"4682_CR30","doi-asserted-by":"crossref","unstructured":"Sandler H, Freedland S, Shore N, et al. Patient (pt) population and radiation therapy (RT) type in the long-term phase 3 double-blind, placebo (PBO)-controlled ATLAS study of apalutamide (APA) added to androgen deprivation therapy (ADT) in high-risk localized or locally advanced prostate cancer (HRLPC). J Clin Oncol. 2022; 40(suppl_16):5084.","DOI":"10.1200\/JCO.2022.40.16_suppl.5084"},{"issue":"17","key":"4682_CR31","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","volume":"388","author":"FC Hamdy","year":"2023","unstructured":"Hamdy FC, Donovan JL, Lane JA et al (2023) Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 388(17):1547\u20131558. https:\/\/doi.org\/10.1056\/NEJMoa2214122. (Epub 2023 Mar 11 PMID: 36912538)","journal-title":"N Engl J Med"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-023-04682-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-023-04682-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-023-04682-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T12:05:22Z","timestamp":1701518722000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-023-04682-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,15]]},"references-count":31,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4682"],"URL":"https:\/\/doi.org\/10.1007\/s00345-023-04682-8","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,15]]},"assertion":[{"value":"20 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Fundaci\u00f3n Jimenez D\u00edaz Hospital at 26\/03\/2019 \/ n\u00ba 06\/19.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Fundaci\u00f3n Jimenez D\u00edaz Hospital at 26\/03\/2019 \/ n\u00ba 06\/19.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}